Abstract: Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions.

Abstract: The present description is related to the field of protein production. It introduces novel host cells with low protease activity, a novel protease regulator, its use in expression systems and protein production, and a method of producing host cells for protein production.

Abstract: Glycine, threonine, and serine can enhance the sensitivity of bacteria to serum, plasma, or whole blood, and therefore can be used as molecules to improve the bactericidal effect of the serum, the plasma, or the whole blood.

Abstract: Provided herein are methods and systems for interfering with viability of bacteria and related compounds and compositions.

Abstract: A specific antibody against a compound of formula (I) wherein X is O, NH, S, CH2; L is a linker that is a divalent spacer; A is an adjuvant or carrier that is an immunogenic molecule or an immunogenic particle; and wherein bonds between linker and saccharide moiety and between linker and carrier are of covalent type; wherein the linker L presents a chemical structure suitable to space the saccharide moiety and the carrier by 7-30 atoms when the adjuvant/carrier A is a biomacromolecule or by 19-30 atoms when the adjuvant/carrier A is a metallic nanoparticle; wherein the carrier/adjuvant A can be selected among a macromolecule, a macrocycle, a dendrimer, a liposome, a nanoparticle, an oligosaccharide featuring from two to five monosaccharidic units or cells like dendritic cells.

Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.

Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.

Abstract: The invention relates to compositions comprising a combination of (a) at least one organic compound which carries at least one thiol group and at least one optionally derivatized carboxyl group, for example L-cysteine, and (b) at least one organic compound selected from the group which is formed from cyclic, organic carbonates, glycerol and its derivatives and C4-C12 fatty acid dimethylamides. Using these low-odor compositions it is possible to reductively decolor colored keratin-containing fibers, in particular human hair, in a rapid and effective manner.

Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.

Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to lipopolysaccharide (LPS) from strains Fisher Devlin (International Serogroups) It-2 (011), It-3 (02), It-4 (01), It-5 (010), It-6 (07), PA01 (05), 170003 (02), IATS016 (02/05), and 170006 (02). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: This invention relates to a bacteriophage MPK6 (deposit number: KCCM 11044P) having a lytic activity to Pseudomonas aeruginosa, or a progeny bacteriophage thereof having a RFLP (Restriction fragment length polymorphism) DNA profile substantially equivalent to the bacteriophage MPK6. The present invention provides a bacteriophage MPK6 or a progeny bacteriophage thereof capable of treating a Pseudomonas aeruginosa infection disease, and suggests an anti-bacterial activity of MPK6 and its progeny bacteriophage using a mammalian and non-mammalian infection model. According to the present invention, the present bacteriophage MPK6 or progeny bacteriophage thereof represents very effective efficacy on treatment of P. aeruginosa-induced peritonitis-sepsis.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Abstract: The present invention relates to a human monoclonal antibody specific for the serotype IATS O11 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.

Abstract: The present invention discloses compositions and methods for treating, preventing and/or monitoring viral, bacterial, eukaryotic protist and/or fungal infections. In some embodiments, these compositions and methods involve human polyclonal antibodies affinity purified from human blood using certain viral, bacterial, eukaryotic protist and/or fungal antigens as described herein. Methods of making the antigenic preparations and the affinity-purified human polyclonal antibodies for passive immunization are also provided.

Abstract: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.

Abstract: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.

Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.

Abstract: This invention provides methods of treating patients having a Staphylococcus infection where the patient also has a low level of Pseudomonas aeruginosa. The methods comprise administering an antagonist of the Pseudomonas Type III Secretion System, e.g., an anti-PcrV antibody antagonist.

Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: The present invention relates to methods for the killing of infectious bacteria by modulating the extra-cellular concentration of bacterial cell signalling molecules. This has the effect of inducing rapid cell death (autolysis) in the majority of bacterial cells, and preventing virulence or restoring a benign state in surviving cells. These receptors have applications for the treatment of individuals with susceptibility to infection, the treatment of patients with existing infections, in disease management, and in related applications where the host for infection is an animal or plant. The compositions described herein are particularly relevant to Pseudomonas aeruginosa infection, for example in the treatment of pulmonary infection in cystic fibrosis patients, and represent a unique bactericidal medication that does not directly target the bacteria.

Abstract: A device that includes a scaffold composition and a bioactive composition with the bioactive composition being incorporated therein or thereon, or diffusing from the scaffold composition such that the scaffold composition and/or a bioactive composition captures and eliminates undesirable cells from the body a mammalian subject. The devices mediate active recruitment, sequestration, and removal or elimination of undesirable cells from their host.

Abstract: An object is to provide: a protein antigen or a peptide antigen usable as a vaccine composition which has an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of clinical isolates derived from patients with a Pseudomonas aeruginosa infection; and an antibody directed against the antigen. The present invention provides a protein antigen or a peptide antigen and an antibody directed against these, which are for use in diagnosis, prevention, or treatment of a disease associated with Pseudomonas aeruginosa. According to the present invention, a protein or a peptide derived from a Pseudomonas aeruginosa-outer membrane protein PA4710, and an antibody directed against these are provided, which are for use in diagnosis, prevention, or treatment of a disease associated with Pseudomonas aeruginosa.

Abstract: An object is to provide an antibody and a vaccine composition which have an ability to practically prevent or treat a Pseudomonas aeruginosa infection, and which can cope with the diversity of clinical isolates derived from patients infected with Pseudomonas aeruginosa. According to the present invention, an antibody against a PA1698 protein that is a type III secretion system component protein of Pseudomonas aeruginosa or against a peptide of the protein, and a vaccine composition comprising the protein or the peptide are provided.

Abstract: The present invention provides improved pharmaceutical compositions and methods of treating or preventing development of bacteremia associated with Pseudomonas aeruginosa infections, where the method comprises administering an antibiotic and an anti-PcrV antibody.

Abstract: The present invention relates in its broadest aspect to combined phage/antibiotic therapy. More particularly, it relates to use of (i) one or more bacteriophages and (ii) one or more antibiotics in the manufacture of a combined product for simultaneous, separate or sequential administration of (i) and (ii) to treat a bacterial infection characterized by biofilm formation, for example an infection comprising or consisting of P. aeruginosa. Treatment in this context may be either therapeutic or prophylactic treatment. Also provided are deposited bacteriophages each exhibiting different strain specificity against P. aeruginosa and combinations of such bacteriophages, e.g. a panel of six deposited bacteriophages which was found to be effective against a high percentage of clinical isolates of P. aeruginosa from canine ear infections.

Abstract: Compounds able to affect production and/or activity of a redox active compound, which include candidate therapeutic compounds and candidate compounds for enhancing power output of a microbial fuel cell, and related compositions, methods and systems.

Abstract: The present application relates to a human monoclonal antibody specific for the serotype IATS 06 of P. aeruginosa, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention relates to methods for producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.

Abstract: The present invention describes a detoxified Gram negative J5 core lipopolysaccharide/group B meningococcal outer membrane protein complex vaccine given in conjunction with CpG 7909 adjuvant. This vaccine composition can be used for either active or passive immunization of mammals for the prevention or treatment of sepsis and infection with Gram negative bacteria. The addition of CpG to the vaccine was shown to markedly increase the antibody response in mice. Furthermore, the ability of the endotoxin vaccine in protecting against Gram-negative bacteria such as Francisella tularensis in vivo is also demonstrated herein.

Abstract: The invention features methods and compositions for treating or preventing Gram-negative bacterial infections.

Abstract: A method of inhibiting, moderating or diagnosing Pseudomonas aeruginosa infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV antigen.

Abstract: A vaccine, effective in inducing the production of antibodies with which to immunize a second subject passively against infection by Gram-negative bacteria and LPS-mediated pathology, comprises a non-covalent polyvalent complex formed between purified, detoxified LPS derived from E. coli and purified outer membrane protein derived from N. meningitidis. The same vaccine will also actively immunize a host subject against Gram-negative bacterial infections and LPS-mediated pathology. Meningococcal infections are included among those Gram-negative bacterial infections protected against by the vaccine.

Abstract: A method of inhibiting, moderating or diagnosing Pseudomonas aeruginosa infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV antigen.

Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.

Abstract: The invention described herein provides for human antibodies produced in non-human animals that specifically bind to Pseudomonas aeruginosa Lipopolysaccharide (LPS). The invention further provides methods for making the antibodies in a non-human animal, expression of the antibodies in cell lines including hybridomas and recombinant host cell systems. Also provided are kits and pharmaceutical compositions comprising the antibodies and methods of treating or preventing pseudomonas infection by administering to a patient the pharmaceutical compositions described herein.

Abstract: The present invention relates to an immunogenic conjugate comprising a carrier molecule coupled to an autoinducer of a Gram negative bacteria. The immunogenic conjugate, when combined with a pharmaceutically acceptable carrier, forms a suitable vaccine for mammals to prevent infection by the Gram negative bacteria. The immunogenic conjugate is also used to raise and subsequently isolate antibodies or binding portions thereof which are capable of recognizing and binding to the autoinducer. The antibodies or binding portions thereof are utilized in a method of treating infections, a method of inhibiting autoinducer activity, and in diagnostic assays which detect the presence of autoinducers or autoinducer antagonists in fluid or tissue samples.

Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to P. aeruginosa mucoid exopolysaccharide. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of P. aeruginosa infection and related disorders (e.g., cystic fibrosis). Some antibodies of the invention enhance opsonophagocytic killing of multiple mucoid strains of P. aeruginosa. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.

Abstract: The present invention relates to methods for the modulation of biofilm formation and antibiotic resistance. Specifically, the present invention identifies the differential expression of biofilm-associated genes in biofilms, relative to their expression in non-biofilm producing bacterial cells. The present invention also identifies the differential expression of biofilm-associated genes in biofilms treated with antibiotic, relative to their expression in untreated biofilms. The present invention describes methods for the diagnostic evaluation of biofilm formation. The invention also provides methods for identifying a compound capable of modulating biofilm formation and antibiotic resistance. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of biofilm-associated diseases or disorders.

Abstract: The present invention relates to use of avian antibodies and/or antigen binding fragments thereof, for the production of a drug for treatment and/or prevention of respiratory tract infection. The drug is administered through local application at the oral cavity and/or pharynx.